Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiuning Le

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2017
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision TherapyDeepa Rangachari, Xiuning Le, Meghan Shea, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2026
Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerabilityGerrina Ruiter, Xiuning Le, Ross A Soo, et al.
NPJ Precision Oncology|July 2, 2025
Progress and challenges of artificial intelligence in lung cancer clinical translationErjia Zhu, Amgad Muneer, Jianjun Zhang, et al.
Translational Lung Cancer Research|June 15, 2026
Lung cancer with <i>EGFR</i> PACC mutations: a practical review of available treatment options and novel therapies on the horizonJulia M Berg, Hollis Viray, Jenna Green, et al.
Cancers|October 14, 2022
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced <i>EGFR</i>-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-AnalysisJianchao Xue, Bowen Li, Yadong Wang, et al.
JTO Clinical and Research Reports|February 16, 2024
Targeting MET in NSCLC: An Ever-Expanding TerritoryYing Han, Yinghui Yu, Da Miao, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphomaPreetesh Jain, Xiuning Le, Ken H Young, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Clinical Lung Cancer|March 28, 2026
Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United StatesXiuning Le, Elizabeth Serra, Kaitlyn Easson, et al.
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2017
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision TherapyDeepa Rangachari, Xiuning Le, Meghan Shea, et al.
Lung Cancer (Amsterdam, Netherlands)|April 3, 2026
Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerabilityGerrina Ruiter, Xiuning Le, Ross A Soo, et al.
NPJ Precision Oncology|July 2, 2025
Progress and challenges of artificial intelligence in lung cancer clinical translationErjia Zhu, Amgad Muneer, Jianjun Zhang, et al.
Translational Lung Cancer Research|June 15, 2026
Lung cancer with <i>EGFR</i> PACC mutations: a practical review of available treatment options and novel therapies on the horizonJulia M Berg, Hollis Viray, Jenna Green, et al.
Cancers|October 14, 2022
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Combination Therapy as First-Line Treatment for Patients with Advanced <i>EGFR</i>-Mutated, Non-Small Cell Lung Cancer: A Systematic Review and Bayesian Network Meta-AnalysisJianchao Xue, Bowen Li, Yadong Wang, et al.
JTO Clinical and Research Reports|February 16, 2024
Targeting MET in NSCLC: An Ever-Expanding TerritoryYing Han, Yinghui Yu, Da Miao, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphomaPreetesh Jain, Xiuning Le, Ken H Young, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Clinical Lung Cancer|March 28, 2026
Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United StatesXiuning Le, Elizabeth Serra, Kaitlyn Easson, et al.
Pageof 18